Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – far from it, as signaled by the potential $2.5 billion deal signed recently ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...
Among the myriad of options available, Blue Scorpion Pain & Inflammation Relief has emerged as a unique and promising alternative. This homeopathic remedy harnesses the potent properties of Blue ...
Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics ... Foresite Capital, Logos Opportunities Fund ...
In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a ...
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research ... Additionally, the recent acquisition of Scorpion by Lilly for a significant sum ...
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...
The biggest buyout in the Boston area was Eli Lilly and Co.’s (NYSE: LLY) agreement to buy a cancer program from Boston-based Scorpion Therapeutics Inc. for up to $2.5 billion in cash.
Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $7.19.
(Bloomberg) -- Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The ...
IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary Glick, Ph.D. Glick previously set up and ran Scorpion Therapeutics, which Eli Lilly is now buying for up to $2.5 ...
LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results